ISCI Announces Medical & Laboratory Director
21 Februar 2013 - 1:30PM
Marketwired
YaFarm Technologies, Inc. (PINKSHEETS: YFRM) (YaFarm, or the
Company) announced today that The Integrative Stem Cell Institute
(ISCI), a premier provider of point-of-care, stem cell-based
therapies, has announced the appointment of Dr Eduardo Cervera
Ceballos, MD as its Medical and Laboratory Director.
Dr Cervera, a licensed hematologist, is currently a Director at
the National Cancer Institute in Mexico City. He is a graduate of
the Autonomous University of the Yucatan and did his post-doctoral
fellowship at the Regional Hospital Locarno and Hospital San
Giovanni in Switzerland. Dr Cervera is a member of several
prestigious associations, including the Internal Medicine
Association of México, the European Society for Medical Oncology,
the American Society of Clinical Oncology and the Oncology Society
of Central American and the Caribbean. Dr Cervera is widely
published with over 4 dozen articles, has developed curriculum for
organizations such as American Society of Hematology, the American
College of Physicians and spoken at several international
conferences.
"Dr Cervera is a highly respected physician and researcher,"
says David Audley, CEO of the ISCI. "He brings years of clinical
experience and laboratory expertise to the ISCI." Dr Cervera will
also serve on the executive leadership of the ISCI and provide
oversight to the laboratory and medical staff of the Institute. "Dr
Cervera," continues Mr Audley, "will provide direct leadership to
the medical and lab services that define our clinical studies. I
have no doubt that under his oversight the ISCI becomes the
standard for the field of regenerative medicine."
About Integrative Stem Cell Institute
(ISCI) The Integrative Stem Cell Institute (ISCI) is a premier
provider of point-of-care, stem cell-based therapies for patients
from around the world. With a state of the art laboratory housed
within the Hospital Galenia in Cancun, Mexico, the ISCI combines
the most advanced scientific application of stem cells with second
to none medical care within the structure of adaptive clinical
trials to effectively track long term outcomes and assure patient
safety. More information on the Integrative Stem Cell Institute is
available at www.iscelli.com
SAFE HARBOR STATEMENT
This press release may contain certain forward-looking
statements and information, as defined within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and is subject to the Safe Harbor
created by those sections. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. This material contains statements about
expected future events and/or financial results that are
forward-looking in nature and subject to risks and uncertainties.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition, adequate financing, and
other material risks. Such forward-looking statements by definition
involve risks, uncertainties and other factors, which may cause the
actual results, performance, or achievements to be materially
different from the statements made herein.
Contact: The Integrative Stem Cell Institute Contact: Miranda
Abrahams Miranda@iscelli.com Investor Contact Atlanta Capital
Partners, LLC David Kugelman (866) 692-6847 info@atlcp.com
Profile Solutions (CE) (USOTC:PSIQ)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Profile Solutions (CE) (USOTC:PSIQ)
Historical Stock Chart
Von Jun 2023 bis Jun 2024